Lisurid in the treatment of Parkinson's disease;Lisurid in der Therapie des Morbus Parkinson

Aktuelle Neurologie

Volumn 25, Issue 4 SUPPL. 4, 1998, Pages

  Horowski, R ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE MALEATE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

BINDING AFFINITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG RECEPTOR BINDING; HALLUCINATION; HUMAN; NEUROLOGIC DISEASE; PARKINSON DISEASE; PSYCHOSIS;

EID: 0032442059     PISSN: 03024350     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1017749     Document Type: Article

References (8)

1. Arzneimittel-Kompendium der Schweiz, 1997
2. Allain, H., A. Destee, H. Petit et al.: Five year follow up of early lisuride and levodopa therapy versus levodopa monotherapy in de novo Parkinson's disease. Fundam. Clin. Pharmacol. (in press)
3. Caldwell, M. A., J.-M. Reymann, H. Allain et al.: Lisuride prevents learning and memory impairment and attentuates the increase in extracellular dopamine induced by transient global cerebral ischemia in rats. Brain Research 771 (1997) 305-318
4. Data sheet Revanil®. December 1990. Great Britain
5. Deutsche Parkinson Studiengruppe, Pharmakotherapie des Morbus Parkinson, Bericht einer Konsensuskonferenz. Neuropsychiatrie 9 (1995) 45-58
6. Fachinformation Dopergin®, Januar 1997, Deutschland
7. Fachinformation Dopergin®, Mai 1995, Österreich
8. Giovanni, P., G. Scigliano, J. Piccolo et al.: Lisuride in de novo Parkinsonian patients: a four-year follow up. Acta Neural. Scand. 77 (1988) 322-327